Targeting systemic and tumor metabolic balances with ketogenic diets enhance efficacy of therapy in FLT3-ITD acute myeloid leukemia.
A special diet enhanced leukemia treatment in lab models, opening a door to test dietary approaches alongside standard cancer therapy.
This Cell Reports study demonstrates that ketogenic diets enhance the efficacy of therapy in FLT3-ITD acute myeloid leukemia by disrupting metabolic balances in preclinical models. The work suggests a dietary intervention strategy that could be tested as an adjunct to AML treatment.
What the study was
- Study design
- Preclinical (in vivo)
- Population
- FLT3-ITD AML models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cell Reports
Why it surfaced
Preclinical AML metabolic intervention study. Score capped at 5 per non-human model rules. Recovered from deferred PMIDs.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.